Abstract Number: 0199 • ACR Convergence 2022
Izokibep, a Novel IL-17A Inhibitor, Improves Patient-reported Outcomes – 16-Week Results from a Placebo-controlled Phase 2 Study in Patients with Active Psoriatic Arthritis
Background/Purpose: Izokibep is a unique IL-17A inhibitor with high potency and small molecular size designed to overcome the limitations of monoclonal antibodies. IL-17 is a…Abstract Number: 0348 • ACR Convergence 2022
Significant Improvement in Cutaneous Lupus Erythematosus with or Without Systemic Lupus Erythematosus with Belimumab Use – a Systematic Review and Meta-Analysis
Background/Purpose: Cutaneous lupus erythematosus (CLE) with or without systemic lupus erythematosus (SLE), can be debilitating and cause significant scarring and psychological distress. Belimumab, a monoclonal…Abstract Number: 0430 • ACR Convergence 2022
The Course of Bone Mineral Density During 8 Years of Treatment with TNF-α Inhibitors in Patients with Ankylosing Spondylitis
Background/Purpose: Bone loss reflected by lower bone mineral density (BMD) compared to age and gender matched healthy controls is a common feature of ankylosing spondylitis…Abstract Number: 0771 • ACR Convergence 2022
The Use of a bDMARD or tsDMARD for the Management of Rheumatic irAE Under Checkpoint Inhibitors: An Observational Study
Background/Purpose: Rheumatic immune related adverse events (irAEs) are observed in about 5 to 10% of cancer patients receiving checkpoint inhibitors (ICIs), with inflammatory arthritis (IA)…Abstract Number: 0887 • ACR Convergence 2022
Comparison of Drug Persistence and Incidence of Tuberculosis Between Tumor Necrosis Factor-α Inhibitors and Tocilizumab as the First-line Biological Treatment in Patients with Rheumatoid Arthritis Using the Korean Health Insurance Review and Assessment Service Database
Background/Purpose: Drug persistence represents long-term therapeutic performance in real clinical setting and tuberculosis (TB) is one of the most important adverse events following biological treatments…Abstract Number: 1040 • ACR Convergence 2022
Impact of Weight and Sex on Long-term Persistence to Secukinumab Treatment in Patients with Active Psoriatic Arthritis or Ankylosing Spondylitis
Background/Purpose: Secukinumab (SEC) has demonstrated a high sustained response rate in patients (pts) with psoriatic arthritis (PsA) or ankylosing spondylitis (AS) across Phase III clinical…Abstract Number: 1403 • ACR Convergence 2022
Herpes Zoster in Rheumatoid Arthritis: Prospective Single University Center Study
Background/Purpose: Patients with Rheumatoid arthritis (RA) have an increased risk of infections due to the disease itself, and/or immunosuppressive therapy. The risk of herpes zoster…Abstract Number: 1558 • ACR Convergence 2022
Prevalence, Phenotypical Clinical Clusters and Treatment of Neurobehçet’s Disease: Study in Northern Spain
Background/Purpose: Behçet's disease (BD) may present with different clinical phenotypes. Ocular and Neurobehçet's Disease (NBD) are severe complications. Data on NBD epidemiology, clinical phenotype and…Abstract Number: 1994 • ACR Convergence 2022
Is Glucocorticoid Bridging Associated with Later Glucocorticoid and Biological DMARD Use in Patients with Rheumatoid Arthritis?
Background/Purpose: Glucocorticoids (GC) are rapidly effective in suppressing disease activity in rheumatoid arthritis (RA), and are often used as 'bridging' therapy while slower acting conventional…Abstract Number: 2131 • ACR Convergence 2022
Minimal Disease Activity Response Patterns in Bio-Naïve Patients Treated with Guselkumab: A Machine Learning Analysis
Background/Purpose: Guselkumab (GUS), a human monoclonal antibody targeting the interleukin-23p19 subunit, demonstrated joint and skin efficacy in patients with active psoriatic arthritis (PsA) in the…Abstract Number: 2273 • ACR Convergence 2022
Waning Vaccine Response After Primary Vaccine Series: Results from the Covid19 Vaccine Response in Rheumatology Patients (COVER) Study
Background/Purpose: Given possible increased risk of COVID-19 in patients with autoimmune conditions, there is a need to better understand the immunogenicity and safety of SARS-CoV-2…Abstract Number: L07 • ACR Convergence 2021
Depletion of KLRG1+ T Cells in a First-in-human Clinical Trial of ABC008 in Inclusion Body Myositis (IBM)
Background/Purpose: Inclusion body myositis (IBM), a relentlessly progressive autoimmune skeletal muscle disease, has no effective available pharmacological therapy. A prominent feature of IBM on microscopy…Abstract Number: L12 • ACR Convergence 2021
Neither Add-on nor Withdrawal of Methotrexate Impacts Efficacy of IL12/23 Inhibition in Active PsA: Data from a Multicenter Investigator-initiated Randomized Placebo-controlled Clinical Trial on Arthritis, Dactylitis, Enthesitis, Psoriasis, QoL and Function
Background/Purpose: Methotrexate (MTX) is often used as first-line DMARD-therapy in active psoriatic arthritis (PsA). Randomized clinical trials usually require treatment failure or intolerance of csDMARD/MTX…Abstract Number: L18 • ACR Convergence 2021
Humoral and Cellular Immune Responses to a Second Dose of COVID-19 Vaccine BNT162b2 in People Receiving Methotrexate or Targeted Immunosuppression: A Cohort Study
Background/Purpose: COVID-19 vaccines have robust immunogenicity in the general population. Data on individuals with immune-mediated inflammatory diseases who are taking immunosuppressants remains limited. Our cohort…Abstract Number: L19 • ACR Convergence 2021
Secukinumab in Giant Cell Arteritis: A Randomized, Parallel-group, Double-blind, Placebo-controlled, Multicenter Phase 2 Trial
Background/Purpose: Little is known about glucocorticoid-sparing agents in giant cell arteritis (GCA) except for IL-6 inhibition. Secukinumab (SEC) has shown significant improvements in the signs…
- « Previous Page
- 1
- …
- 34
- 35
- 36
- 37
- 38
- …
- 54
- Next Page »